Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events
High-dose steroids, particularly when started early, are associated with significantly worse survival after irAEs in metastatic solid tumors. These findings support managing irAEs with the lowest effective steroid dose and encourage exploration of steroid-sparing strategies. Subtype-specific analyses were limited by small sample sizes and should be interpreted cautiously.
Authors
- Haydar Çağatay Yüksel (ORCID: https://orcid.org/0000-0001-8857-2983)
- Erdem Göker (ORCID: https://orcid.org/0000-0001-6180-713X)
- Caner Acar (ORCID: https://orcid.org/0000-0002-9782-6807)
- Burcak S. Karaca (ORCID: https://orcid.org/0000-0003-2638-1625)
- Gökhan Şahin (ORCID: https://orcid.org/0000-0003-1478-9383)
- Fatma Pinar Açar
Institutions
- Ege University (TR)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1080/14737140.2026.2614710
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00